Drug Warning: Pargluva
Generic name: muraglitazar (a new class of drugs known as dual PPAR-agonists)
Manufactured and marketed by: Bristol-Myers Squibb and Merck
Purpose: Used for type 2 diabetes patients in order to control their blood sugar and improve cholesterol levels by stimulating certain receptors in cells that are responsible for regulating fat and sugar.
Side Effects Reported
- An article appeared on the web page of the Journal of the American Medical Association that cited significant heart attack and stroke risks from the new drug.
- Reports show that those taking Pargluva had approximately twice the risk of heart attack, stroke, or death compared to placebo patients.
- In Pargluva trials, 2.11 percent of patients who were treated with Pargluva suffered cardiovascular problems ranging from heart attack and stroke to congestive heart failure.
Industry Report
An editorial by Dr. James M. Brophy of McGill University in Montreal that was printed with the article indicated that there might also be a cancer risk associated with Pargluva. The editorial by Brophy also mentions that the data reported to the FDA "may have fostered an illusion of safety," and Dr. Brophy detailed multiple instances where the manner in which patient trials were conducted may have been slanted in favor of approval of Pargluva.
Seeger Weiss is not currently pursuing lawsuits on this drug, but its drug warnings will remain on our radar.
- Asbestos
- Class Actions
- Commercial Litigation
- Defective Products
- Drug Injury
- Personal Injury
- Securities Fraud
- Toxic Exposure
- Accutane Side Effects
- Darvon and Darvocet
- DePuy Hip Recall
- Fosamax Femur Fractures
- Muscle Injury
- SSRI Birth Defects
- Topamax Birth Defects
- Transvaginal Surgical Mesh and Bladder Slings
- Tylenol Liver Damage
- Zocor/Simvastatin
